ENTEROME
LIVE

Serial Number

79126292

Owner

ENTEROME

Attorney

Thomas M. Palisi

Filing Date

Jan 3, 2013

Add to watchlist:

No watchlists yet
View on USPTO

ENTEROME Trademark

Serial Number: 79126292 • Registration: 4561761

ENTEROME is a trademark filed by ENTEROME on January 3, 2013. The trademark is classified under Class 1 (Chemicals), Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

ENTEROME (4 trademarks)

94-96, Avenue Ledru Rollin
Paris 75011 , FR

Entity Type: 03

Trademark Details

Filing Date

January 3, 2013

Registration Date

July 8, 2014

Published for Opposition

January 14, 2014

Goods & Services

[ Cosmetic products, namely, cosmetic creams ]

Human pharmaceutical research; research services provided by a pharmaceutical laboratory, namely, providing medical research testing services in the field of metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation, and irritable bowel syndrome; Providing medical and scientific research information in the field of metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation, and irritable bowel syndrome; providing medical and scientific research information in the field of pharmaceutical and clinical trials; scientific laboratory services, genetic testing of laboratory animals for pharmaceutical research purposes; biological research in the fields of microbiology and chemistry

Pharmaceutical and medicinal products for human and veterinary use, namely, pharmaceutical preparations for treating metabolic disorders, immunological disorders, cancers, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome; veterinary products, namely, anti-infective products for veterinary use, veterinary pharmaceutical preparations for treatment of metabolic disorders, immunological disorders, cancers, central nervous systems disorders, gastroenterological disorders, infectious diseases and diarrhea; medicinal products for human and veterinary use, namely, nutritional supplements containing probiotic compositions; sanitary products for use in medicine, namely, sanitary sterilizing preparations, disinfectants for sanitary purposes, sanitary preparations for medical use; dietetic food and substances for medical use in the nature of meal replacement products and prepackaged meal plans, namely, nutritional meal replacement bars adapted for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome, prepared, prepackaged entrees for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome, prepared, prepackaged snack foods for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome, prepared, prepackaged yogurts for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome, prepared, prepackaged desserts for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome; nutritional supplements for medical use; food additives for medical use, namely, dietary fiber for treating metabolic disorders, gastroenterological disorders, diarrhea, constipation and irritable bowel syndrome; nutritional food additives for medical purposes in the nature of natural food extracts derived from fish, meat, vegetables, microorganisms and crops

[ Chemical and biochemical substances used for the manufacture and preservation of foodstuffs, of pharmaceutical, cosmetic and veterinary products, namely, probiotic bacteria and probiotic bacterial cultures for use in the manufacture of food products and pharmaceutical preparations, prebiotic bacteria and prebiotic bacterial cultures for use in the manufacture of food products and pharmaceutical preparations, enzymes for use in the manufacture of food products and pharmaceutical preparations ]

Filing History

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Dec 22, 2025 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Apr 22, 2025 NA71
REGISTERED-SEC.71 ACCEPTED
Apr 22, 2025 71AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 21, 2025 APRE
TEAS SECTION 71 RECEIVED
Dec 9, 2024 ES71
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Jul 8, 2023 REM4
INTERNATIONAL REGISTRATION RENEWED
Jan 26, 2023 RNWL
PARTIAL INVALIDATION PROCESSED BY THE IB
Dec 12, 2021 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Nov 4, 2021 INPS
INVALIDATION PROCESSED
Nov 4, 2021 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Oct 10, 2021 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Feb 10, 2021 NA75
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
Feb 10, 2021 C75P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 10, 2021 APRE
TEAS SECTION 71 & 15 RECEIVED
Dec 29, 2020 ES75
FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 23, 2015 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 4, 2014 FICS
FINAL DISPOSITION PROCESSED
Dec 4, 2014 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 8, 2014 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 8, 2014 R.PR
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
May 30, 2014 ETOP
EXTENSION OF TIME TO OPPOSE RECEIVED
Feb 12, 2014 ETOF
PUBLISHED FOR OPPOSITION
Jan 14, 2014 PUBO
NOTIFICATION PROCESSED BY IB
Jan 11, 2014 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 25, 2013 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 25, 2013 OP2R
NOTICE OF PUBLICATION
Dec 25, 2013 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Dec 6, 2013 PREV
ASSIGNED TO LIE
Dec 2, 2013 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 7, 2013 CNSA
EXAMINERS AMENDMENT MAILED
Oct 22, 2013 CNEA
EXAMINER'S AMENDMENT ENTERED
Oct 22, 2013 XAEC
EXAMINERS AMENDMENT -WRITTEN
Oct 22, 2013 CNEA
REFUSAL PROCESSED BY IB
May 15, 2013 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 22, 2013 RFCS
REFUSAL PROCESSED BY MPU
Apr 22, 2013 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 20, 2013 RFCR
NON-FINAL ACTION WRITTEN
Apr 19, 2013 CNRT
ASSIGNED TO EXAMINER
Apr 17, 2013 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 15, 2013 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 11, 2013 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 7, 2013 REPR